

Supplemental Table 1: Comparison of baseline clinical and tumor characteristics, including PET-derived values, between patients with controlled and uncontrolled disease. Values are presented as mean \pm SD or number of patients.

	Controlled (n = 23)	Uncontrolled (n = 19)	p-value
Age (years)	63 \pm 10	58 \pm 12	0.128
Sex			0.536
Male	13	8	
Female	10	11	
Ki67 (%)	4.5 \pm 5.1	9.9 \pm 12.3	0.025
Time between diagnosis and PRRT (months)	63 \pm 51	48 \pm 40	0.300
IBI			0.267
0	20	13	
> 0	3	5	
Baseline SUV _{max}	29.3 \pm 9.5	22.4 \pm 8.9	0.022
Baseline SUV _{mean}	12.7 \pm 3.6	10.1 \pm 2.8	0.012
Baseline TV (ml)	453 \pm 477	591 \pm 785	0.860
Baseline TLA (SUV*ml)	5935 \pm 6080	6088 \pm 8323	0.668
Baseline SUV _{T/S}	2.03 \pm 1.07	1.52 \pm 1.05	0.075

Ki67: Ki-67 proliferation index; PRRT: peptide receptor radionuclide therapy; IBI: inflammation-based-index; SUV: standardized uptake value; TV: tumor volume; TLA: total lesion activity; T/S: tumor-to-spleen ratio